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Activated Stat5 trafficking 
Via Endothelial Cell-derived 
Extracellular Vesicles Controls IL-3 
Pro-angiogenic Paracrine Action
Giusy Lombardo*, Patrizia Dentelli*, Gabriele Togliatto, Arturo Rosso, Maddalena Gili, 
Sara Gallo, Maria Chiara Deregibus, Giovanni Camussi & Maria Felice Brizzi
Soluble factors and cell-derived extracellular vesicles (EVs) control vascular cell fate during 
inflammation. The present study investigates the impact of Interleukin 3 (IL-3) on EV release by 
endothelial cells (ECs), the mechanisms involved in EV release and paracrine actions. We found that IL-3 
increases EV release, which is prevented by IL-3Ralpha blockade. EVs released upon IL-3 stimulation 
were able to induce pro-angiogenic signals as shown by chromatin immunoprecipitation (ChIP) assay 
performed on the promoter region of cyclin D1 and tridimensional tube-like structure formation.  
We herein demonstrate that these effects rely on the transfer of miR-126-3p, pre-miR-126 and, more 
importantly, of activated signal transduction and activator of transcription 5 (pSTAT5) from IL-3-EV 
cargo into recipient ECs. We show, using the dominant negative form (ΔN)STAT5 and an activated 
STAT5 (1*6STAT5) constructs, that STAT5 drives IL-3-mediated EV release, miR-126-3p and pSTAT5 
content. Finally, using EVs recovered from ΔNSTAT5 expressing ECs, we provide evidence that miR-
126-3p and pSTAT5 trafficking is relevant for IL-3-mediated paracrine pro-angiogenic signals. These 
results indicate that IL-3 regulates EC-EV release, cargo and IL-3 angiogenic paracrine action via STAT5. 
Moreover, these results provide evidence that EC-derived IL-3-EVs can serve as pro-angiogenic clinical 
delivery wound healing devices.
Interleukin 3 (IL-3) was originally implicated in the survival, proliferation and differentiation of hematopoietic 
progenitor/stem cells and in the functional activation of mature cells1,2. However, the contribution of IL-3 to 
vascular cell proliferation/activation, first suggested by Orazi et al.3, has recently been extensively documented4–8. 
IL-3 is mainly produced by activated T lymphocytes and mast cells9,10 in physiological and pathological set-
tings11. Besides acting on mature endothelial cells (ECs), IL-3 promotes the expansion and arterial specifica-
tion of endothelial progenitor cells5, while also inducing the proliferation and migration of smooth muscle cells 
(SMCs)12. IL-3’s action, both in hematopoietic and vascular cells, mainly depends upon the activation of STAT5s, 
whose expression is under the control of one of the most relevant vascular-specific small non-coding RNAs 
(miR), miR-2228. The last decade has seen miRs gaining particular attention in their role as post-transcriptional 
regulators of genes that are involved in cell differentiation, growth and function13. Collectively defined as exRNA, 
miRs, mRNA and long, non-coding RNA (lncRNA) have recently been detected encapsulated in vesicles in cir-
culation14–16. Vesicles have distinct biogenesis or cell origin17. The term “exosomes” is usually reserved for vesicles 
derived from the endosomal membrane compartment by exocytosis, whereas “ectosomes/microvesicles” define 
vesicles generated by the budding of cell plasma membranes18. In fact, the more inclusive term “extracellular ves-
icles” (EVs) has been suggested, given the overlap in characteristics and biological activities that exists between 
exosomes and ectosomes/microvesicles19. EVs have recently emerged as a well-preserved evolutionary mecha-
nism of cell-to-cell communication19.
EVs that are released by a given cell type may function within a defined microenvironment (paracrine action) 
or may even act at a distance from the cell of origin (endocrine action). EVs contain surface proteins and cyto-
plasmic molecules from their cell of origin and can therefore impact target cell functional capabilities20,21. In 
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particular, EV biological activity has been linked to the transfer of receptors, lipids, proteins and exRNA that may 
change both the phenotype and function of recipient cells14,21,22. While EVs are constitutively released by cells, 
their release can be enhanced23 in response to cell activation or stress. However, the signaling mechanisms that 
account for EV release have only been partially investigated.
The aim of this present study is to investigate whether the inflammatory cytokine IL-3 exerts angiogenic 
paracrine effects via EC-EV release. Moreover, the signaling pathway(s) associated with IL-3-induced EV release, 
cargo and biological effects have also been investigated.
Results
IL-3 challenge increases the number of EVs released from ECs and improves their pro-angio-
genic capability. It has been widely reported that ECs can release EVs24–27. We herein investigate whether 
differences in EV release can occur when ECs are subjected to inflammatory stimuli, such as IL-3. Figure 1a,b 
shows that differences in EV number per cell, but not in EV size, were detected by Nanosight. Moreover, EVs 
evaluated in this study were in the range of nanometers as shown by transmission electron microscopy of EVs 
(Supplementary Fig. S1a). On these bases, we can reasonably assume that the effect of IL-3 is independent of 
EC proliferation. The existence of EVs of EC origin was demonstrated by analyzing surface markers (Fig. 1c,d, 
Supplementary Fig. S2–S4). ECs were pre-treated with an anti-IL-3Ralpha blocking antibody 30 minutes before 
IL-3 treatment to demonstrate the role of IL-3 in mediating EV release. As reported in Fig. 1a–d, IL-3 blockade 
Figure 1. Characterization of EC-derived EVs. (a) Number of EV particles (mean ± SEM) calculated per 
cell at isolation. Data refer to EVs from ECs (EVs), IL-3-treated ECs (IL-3-EVs) or from ECs pre-treated with 
the anti-IL3Ralpha blocking antibody (anti-IL-3R) and then stimulated with IL-3 (anti-IL-3R-EVs). The anti-
IL-3R alone was also used. The results are representative of four different experiments performed in triplicate 
(n = 4) (***p < 0.001, IL-3-EVs vs EVs; **p < 0.01 and anti-IL-3R-EVs). (b) Representative images of NanoSight 
analyses performed on the 100 k fraction of EC-derived EVs. Curve 1: relationship between particle distribution 
(left y axis) and particle size (x axis); curve 2: correlation between cumulative percentage distribution of 
particles (percentile in right y axis) and particle size (x axis). The results are representative of four different 
experiments performed in triplicate (n = 4). (c) Table resuming FACS analyses of EV surface markers (CD81, 
CD105, c-Kit/CD117, CD31, KDR and CD146, expressed as percentage of expression ± SD) (n = 5). (d) CD63 
western blotting analysis on EC-derived EVs (n = 5).
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inhibits IL-3-induced EV release, without affecting EV size. To evaluate whether EVs released upon IL-3 treat-
ment might act as paracrine factors for neighboring cells, EVs labeled with PKH26 dye were assayed for EC inter-
nalization. Figure 2a and Supplementary Fig. S1b show that EVs can be incorporated by ECs. Functional studies 
were performed using EVs from either unstimulated ECs, from IL-3-treated ECs (IL-3-EVs) or from IL-3-treated 
ECs that had been pre-incubated with the anti-IL-3Ralpha antibody (anti-IL-3R-EVs). Figure 2b–d shows that 
IL-3-EVs are more efficient than normal EVs in inducing tube-like structure formation, STAT5 activation and 
cyclin D1 expression. That this effect depends on IL-3 stimulation is sustained by the inhibitory effect observed 
when anti-IL-3R-EVs were assayed in the functional assay (Fig. 2b–d). mRNA and protein assays confirmed the 
absence of IL-3 in IL-3-EVs (Supplementary Fig. S5a,b). The ELISA assay excludes the presence of IL-3 bound to 
IL-3-EVs (Supplementary Fig. S5c).
IL-3 treatment leads to EV miR-126-3p accumulation. EV biological activity has been linked to 
the transfer of proteins, lipids and exRNA, including miRs, into recipient cells14,21,22. In our experimental con-
ditions EVs released by untreated or IL-3-treated ECs showed the presence of small RNA classes, as obtained 
by a bioanalyzer profile on total RNA of EVs (Supplementary Fig. S1c). We have previously shown that IL-3 
Figure 2. IL-3 improves the pro-angiogenic potential of EC-derived EVs. (a) Representative images obtained 
on a confocal microscope of ECs treated for 1 h with the indicated PKH26-labeled EVs to evaluate up-take of 
EVs by ECs. The results are representative of four different experiments performed in triplicate (n = 4). Scale 
bars indicate 10 μ m. (b) Representative photomicrographs of an in vitro angiogenesis assay, showing tube-like 
structure formation by ECs, either alone or in the presence of IL-3 (10 ng/ml), EVs, IL-3-EVs or anti-IL-3R-
EVs. The quantitative analysis of the number and length of branches and percentage of vessel area (% area) of 
in vitro formed vessel-like structures is reported as mean ± SD. The results are representative of four different 
experiments performed in triplicate (n = 4) (for length, **p < 0.01 IL-3 vs none and IL-3-EVs vs anti-IL-3R-
EVs; for % area, ***p < 0.001 IL-3 vs none, *p < 0.05 IL-3-EVs vs EVs and anti-IL-3R-EVs; for n° of branches, 
***p < 0.001 IL-3 vs none. IL-3-EVs vs EVs, *p < 0.05 IL-3-EVs vs anti-IL-3R-EVs). Scale bars indicate 50 μ m. 
(c,d) ECs either alone or stimulated with IL-3 (10 ng/ml), EVs, IL-3-EVs or anti-IL-3R-EVs were lysed and 
analyzed for pSTAT5 (c) and cyclin D1 (d) content. Protein level was normalized to STAT5 and β -actin 
content, respectively. The results are representative of four different experiments performed in triplicate (n = 4) 
(pSTAT5, **p < 0.01 IL-3 vs none, IL-3-EVs vs EVs and anti-IL-3R-EVs; cyclin D1, **p < 0.01 IL-3 vs none, 
*p < 0.05 IL-3-EVs vs EVs and anti-IL-3R-EVs).
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changes miR-221/222 content in ECs8. We herein evaluate the effect of IL-3 on miR EV cargo. In particular, 
miR-126-3p and miR-126-5p content28–30 was analyzed and compared with its cellular content. miR-221/222 
was used as an internal control. miR-221/222, and miR-126-5p were reduced in ECs upon IL-3 stimulation 
(Fig. 3a and Supplementary Fig. S6a). No significant changes in miR-126-3p cellular content were detected 
(Fig. 3a). miR content in EVs was therefore evaluated. Figure 3b shows that miR-126-3p, but not miR-221/222, 
was increased in IL-3-EVs. While reduced EV miR126-5p levels were detected (Supplementary Fig. S6b). As 
expected, IL-3R blockade prevented the transfer of miR-126-3p into EVs (Fig. 3b) and returned miR126-5p to 
basal levels (Supplementary Fig. S6b). A significant increase of miR126-3p IL-3-EV content was found even 
when normalized for its cellular content (Fig. 3c) or when snoRNU48 house-keeping gene was used (data not 
shown). As only miR126-3p was increased in EVs and its increased expression correlates with angiogenesis28, 
transfer of miR-126-3p into recipient ECs was evaluated to investigate its role in IL-3-EV-mediated biological 
response. Data reported in Fig. 3d demonstrate that, indeed, miR-126-3p content increased in ECs subjected to 
IL-3-EVs. It has been reported that EVs from different stem cell sources contain miRs in their precursor form31,32. 
We therefore investigated this possibility in our experimental conditions. Indeed, pre-miR-126 was significant 
increased in IL-3-EVs and its transfer into EVs could be prevented by IL-3R blockade (Supplementary Fig. S6c). 
That miR-126-3p and pre-miR-126 could be transferred from IL-3-EV cargo into ECs is sustained by the results 
obtained pre-treating ECs with α –amanitin before IL-3-EV challenge (Fig. 3e and Supplementary Fig. S6d). 
Functional studies which investigate the possibility that miR-126-3p transfer contributes to the IL-3-EV-mediated 
pro-angiogenic effect were performed using EVs that had been depleted of miR-126-3p (Supplementary Fig. S7). 
As shown in Fig. 3f, tube-like structure formation was impaired, but not completely abrogated upon the use of 
miR-126-3p-depleted IL-3-EVs.
IL-3 drives pSTAT5 EV content and IL-3-EV biological effects. A growing amount of evidence indi-
cates that the transfer of proteins into recipient cells could also account for EV biological response17–20. Thus, 
we have also evaluated the content of one of the most relevant IL-3 signaling molecules in EVs, STAT55,8,33. We 
found slightly increased STAT5 content in IL-3-EVs than in EVs. By contrast, we demonstrate that IL-3 drives 
pSTAT5EV content, as shown in Fig. 4a. pSTAT5 was not found in EVs that had been recovered from IL-1β – 
and TNFα -stimulated ECs (Fig. 4b). In order to evaluate the role of IL-3-EV pSTAT5 cargo, biochemical and 
functional studies were performed using EVs recovered from ECs that were transfected with the Δ NSTAT5 con-
struct and stimulated with IL-3 (IL-3-Δ N-EVs) or that express the constitutive active STAT5A (1*6STAT5-EVs). 
Transfection efficacy and specificity were confirmed by western blot analysis. STAT5 activation, unlike in STAT3, 
was regulated by transfection (Fig. 4c). STAT5 content was further evaluated in EVs recovered from transfected 
ECs. Interestingly, 1*6STAT5-EVs recapitulated IL-3-EV protein cargo (Fig. 4d,e) while the IL-3-Δ N-EVs were 
impaired in both STAT5 and pSTAT5 content. Further to these results, only ECs stimulated with 1*6STAT5-EV 
underwent STAT5 activation and cyclin D1 expression (Fig. 5a,b). IL-3 was added to ECs subjected to 
1*6STAT5-EV without further effects (data not shown). Thus, we inquired whether IL-3-EV–elicited cyclin D1 
expression depended on STAT5-cyclin D1 gene targeting. A ChIP assay, which was performed on the promoter 
region of cyclin D134, clearly demonstrates that the increased level of activated STAT5 leads to the formation of a 
STAT5 transcriptional complex which binds to the cyclin D1 promoter (Fig. 5c). Finally, functional experiments 
performed using either IL-3-Δ N-EVs or 1*6STAT5-EVs demonstrated that IL-3-Δ N-EV-stimulated ECs have an 
impaired capability to form tube-like structures. Conversely, 1*6STAT5-EVs recapitulated the effect of IL-3-EVs 
(Fig. 6a). Moreover, the relevance of pSTAT5 intracellular content in regulating EC functional activities was sus-
tained by the observation that both IL-3 and IL-3-EVs failed to promote tube-like structure formation when 
a Δ NSTAT5 construct was transfected into recipient cells (Fig. 6b). These data as well as the observation that 
IL-3-EVs did not induce IL-3 expression in ECs (Supplementary Fig. S5a) support the notion that IL-3 transfers a 
functional transcriptional factor to neighboring ECs, by means of EVs, that could alternatively direct its biological 
response.
STAT5 dictates the release of EV and miR-126-3p cargo upon IL-3. The results reported above led 
us to investigate whether STAT5 is able to control IL-3-mediated EV release and miR-126-3p content. To this 
end, the number of EVs released from transfected ECs was analyzed. Figure 7a shows that IL-3-Δ NSTAT5 con-
struct expression significantly reduces the number, but not the size (Supplementary Fig. S8a) of EVs released in 
response to IL-3. That EC-EV release depends on IL-3-mediated STAT5 activation was further sustained by the 
number of EVs recovered from IL-3-stimulated ECs pre-treated with a specific JAK2 inhibitor (Supplementary 
Fig. S8a–c). EV miR-126-3p cargo was also analyzed. Data reported in Fig. 7b demonstrate that IL-3-Δ N-EVs 
carry reduced miR-126-3p content. No significant differences in miR-126-3p cellular content were found after 
transfection (Fig. 7c). Moreover, the transfer of pSTAT5 (Fig. 5a) and miR-126-3p into ECs that had been stimu-
lated with IL-3-Δ N-EVs was reduced (Fig. 7d). As expected, the number of EVs released by ECs expressing the 
1*6STAT5 construct was almost comparable to values obtained upon IL-3 treatment. Likewise, miR-126-3p EV 
cargo and miR-126-3p transfer into ECs were rescued even in the absence of IL-3 stimulation (Fig. 7b,d). These 
results demonstrate that the activation of the STAT5 signaling pathway is crucial for IL-3-mediated EV release 
and cargo.
IL-3-EV miR-126-3p content is relevant for Erk1/2 activation. The reduced IL-3-Δ N-EV miR-
126-3p content led us to evaluate the contribution of miR-126-3p to IL-3-EV angiogenic property. The miR-
126-3p target, Spred-128,35, was therefore evaluated in ECs treated with IL-3-Δ N-EVs and compared with those 
stimulated with miR-126-3p -depleted IL-3-EVs. Results reported in Fig. 7e demonstrate that Spred-1 increased 
under both experimental conditions, while it was almost undetectable in ECs stimulated with IL-3-EVs or 
1*6STAT5-EVs. The activation of Erk1/2 inversely correlates with Spred-1 expression (Fig. 7f). These data provide 
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further evidence that EV miR-126-3p and pSTAT5 content cooperate in mediating IL-3-EV paracrine effects. An 
independent cooperation between these signaling pathways is also supported by the observation that IL-3 was 
still able to induce Erk1/2 activation in ECs depleted of STAT5 (Fig. 7g).
Figure 3. IL-3 dictates the content of miR-126-3p in EC-derived EVs. (a) miR‐126-3p, miR-221 and miR-222 
expression was evaluated by quantitative real-time PCR (qRT-PCR) on ECs, untreated (c) or treated with IL-3 
(IL-3) in the presence or in the absence of the anti-IL3Ralpha blocking antibody (anti-IL-3R). Data normalized 
to RNU6B are representative of four different experiments performed in triplicate (n = 4) (p = 0.056 IL-3 vs 
none and p = 0.075 IL-3 vs anti-IL3R+ IL-3 for miR-126-3p; p = 0.0003 IL-3 vs none and p = 0.0001 IL-3 vs 
anti-IL3R+ IL-3 for miR-221: p = 0.04 IL-3 vs none and p = 0.008 IL-3 vs anti-IL3R+ IL-3 for miR-222) (b) 
miR‐126-3p, miR-221 and miR-222 expression was evaluated as above on EVs recovered from ECs, treated as 
above (n = 5) (p = 0.01 IL-3-EVs vs EVs and p = 0.04 IL-3-EVs vs anti-IL3R-EVs for miR-126-3p; p = 0.7  
IL-3-EVs vs EVs and p = 0.9 IL-3-EVs vs anti-IL3R-EVs for miR-221: p = 0.2 IL-3-EVs vs EVs and p = 0.5  
IL-3-EVs vs anti-IL3R-EVs for miR-222). (c) miR‐126-3p expression evaluated on EC-derived EVs was 
normalized to EC miR‐126-3p content. Data are representative of five experiments performed in triplicate 
(n = 5) (p = 0.03 IL-3-EVs vs EVs and p = 0.02 IL-3-EVs vs anti-IL-3R-EVs). (d) miR‐126-3p expression was 
evaluated by qRT-PCR on ECs untreated or treated with EVs derived from ECs stimulated as above. Data 
normalized to RNU6B are representative of four different experiments performed in triplicate (n = 4) (p = 0.004 
EC+ IL-3-EVs vs EC+ EVs and p = 0.02 EC+ IL-3-EVs vs EC+ anti-IL-3R-EVs). (e) ECs incubated in the 
presence of 50 μ g/ml of α -amanitin to inhibit EC transcription were stimulated or not stimulated with EVs 
or IL-3-EVs. EV-miR-126 transfer was evaluated by q-RT-PCR. The difference in Ct values (Δ Ct) between 
α -amanitin-treated ECs alone or with the indicated EVs is reported (p = 0.001) (mean ± SD). (f) Representative 
photomicrographs of an in vitro angiogenesis assay performed on ECs treated as indicated. The quantitative 
analysis of the number and length of branches and percentage of area of in vitro formed vessel-like structures 
is reported as mean ± SD. The results are representative of four different experiments performed in triplicate 
(n = 4) (for length, ***p < 0.001 EC+ IL-3-EVs vs EC+ EVs; for % area **p < 0.01 ECs+ IL-3-EVs vs ECs+ EVs, 
*p < 0.05 ECs+ anti-miR-126 IL-3-EVs vs ECs+ IL-3-EVs). Scale bars indicate 50 μ m.
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Discussion
We have shown in the present study that IL-3 promotes pro-angiogenic paracrine effects via EC-derived EVs. In 
particular, we have noticed that IL-3 upholds EC-EV release and increases EV miR-126-3p and pSTAT5 content. 
This translates into the transfer of functional miR-126-3p and STAT5 into ECs which leads to cyclin D1 transcrip-
tion and tridimensional tube-like structure formation. We also found that functional STAT5 drives EV release, 
IL-3-EV cargo and biological activity. Finally, we noticed that enrichment in functional STAT5 and miR-126-3p is 
sufficient to facilitate the signaling functions of IL-3-EVs. These results indicate that IL-3 impacts on EC-derived 
EV functional capability and provide evidence for IL-3-EVs’ involvement, as paracrine factors, in the physiologi-
cal and pathological processes of wound healing.
IL-3, originally described as a hematopoietic growth factor, also exerts relevant action on the vascular wall 
during inflammation36. Its role in inflammation has been underlined further by Weber et al.37. IL-3, mainly pro-
duced by activated lymphocytes, can induce EC activation38, smooth muscle cell proliferation12, endothelial pro-
genitor cell expansion5 as well as neoangiogenesis8. In the present study, we investigated IL-3-mediated paracrine 
actions. There is increasing evidence to suggest that EVs act as a well-preserved cell-to-cell communication mech-
anism which impacts on both neighboring and remote cells in physiological and pathological settings19,21. EVs 
have different effects on the endothelium depending on their cell of origin; however no data on EC-derived EV 
paracrine effects in response to IL-3 are currently available. We have shown herein that the number of EC-derived 
EVs can be increased by stimulating ECs with IL-3 and that IL-3-EVs, independently of IL-3 (IL-3 was detected 
neither in IL-3-EVs nor in ECs upon IL-3-EV treatment), are effective in inducing pro-angiogenic signals when 
used to stimulate ECs. As a matter of fact, IL-3-EVs induce the activation of STAT5 and the expression of cyclin 
Figure 4. IL-3 treatment drives pSTAT5 EV content. (a) EVs recovered from ECs, untreated (EVs) or treated 
with IL-3 (IL-3-EVs), in the presence or in the absence of anti-IL3Ralpha blocking antibody (anti-IL-3R-EVs) 
were analyzed by western blotting for pSTAT5 and STAT5 content and normalized to CD63 content. The results 
are representative of four different experiments performed in triplicate (n = 4) (p < 0.01 IL-3-EVs vs EVs and 
anti-IL-3R-EVs for pSTAT5; p < 0.05 IL-3-EVs vs EVs and anti-IL-3R-EVs for STAT5). (b) EVs recovered from 
untreated or IL-3-, IL-1β - or TNF-α -treated ECs were lysed and analyzed for pSTAT5 and STAT5 content and 
normalized to CD63 content (n = 4) (p < 0.001 IL-3-EVs vs EVs for pSTAT5; p < 0.05 IL-3-EVs vs EVs for 
STAT5). (c) Cell extracts from ECs, transfected or not with Δ NSTAT5 or 1*6STAT5 constructs for 48 h, and 
treated as indicated, were subjected to SDS-PAGE to evaluate pSTAT5, STAT5, pSTAT3 and STAT3 content. 
Data are representative of four different experiments performed in triplicate (n = 4) (p < 0.001 IL-3 vs none, 
Δ NSTAT5 vs IL-3, 1*6STAT5 and 1*6STAT5+ IL-3 vs Δ NSTAT5). (d,e) EVs recovered from untreated, IL-
3-treated or Δ NSTAT5-transfected ECs in the presence of IL-3 (IL-3-Δ N-EVs) or 1*6STAT5-transfected 
ECs (1*6STAT5-EVs) were analyzed for pSTAT5 (d) and STAT5 (e) content and normalized to CD63 (n = 4) 
(p < 0.01 IL-3-EVs vs EVs and IL-3-Δ N-EVs, 1*6STAT5-EVs vs EVs for pSTAT5; p < 0.01 IL-3-Δ N-EVs vs all 
experimental groups for STAT5).
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D1 as well as tridimentional, tube-like structure formation. We also demonstrate that IL-3-EV actions rely on the 
transfer of their cargo into ECs. Increased miR-126-3p content can be detected in ECs stimulated with IL-3-EVs. 
Selective EV-miR and pre-miR availability has been suggested to represent a rapid means of regulating gene 
expression14–16,31,32. As a matter of fact, our functional studies and the activation of the Erk1/2 signaling pathway 
indicate that functional miR-126-3p and its precursor form, released into the tissue microenvironment via EVs, 
in response to IL-3, could be transferred into recipient cells and rapidly induce pro-angiogenic signals.
We did not investigate the specific role of miR126-5p in our experimental conditions. However, the finding 
that miR126-5p is down-regulated in response to IL-3 is in agreement with the observation that low EC miR-
126-5p levels could participate in the control of leucocyte trafficking30 and with our original data38 demonstrating 
that IL-3 can promote EC activation and leukocyte adhesion. Our data suggest that also EVs, via paracrine mech-
anisms, could participate to such effect. However, further studies are required to address this issue.
EVs can possess pro-angiogenic properties26,39 when transferring metalloproteinases MMP-2 and MMP-9, 
which support matrix degradation and new blood vessel formation35,40. In addition, their protein content means 
that EVs have been also considered signalosomes41,42. Indeed, EVs may trigger intracellular signaling pathways 
by engaging receptors, ligands and by transferring functionally active receptors, such as CCR543, EGFRvIII44 
and MET45. We herein demonstrate that, upon IL-3 stimulation, EVs released from ECs carry the IL-3 specific 
signaling molecule STAT5, which triggers a specific signaling pathway when transferred into recipient cells. Data 
on death receptor ligands46,47, have suggested that functional molecules are more active when delivered by EVs 
than in their soluble forms. Indeed, our data demonstrate that IL-3-EVs mainly transfer the activated form of 
STAT5 to recipient cells, unlike EVs released by other inflammatory stimuli such as IL-1β and TNFα . Although 
we have no additional evidences on EC-derived EV content upon IL-1β – and TNFα –treatment, we can speculate 
Figure 5. EV pSTAT5 content leads to the formation of a STAT5/cyclin D1 transcriptional complex.  
(a,b) Cell extracts from ECs treated with EC-derived EVs, as indicated, were analyzed for pSTAT5 and STAT5 
(a) or for cyclin D1 (b) and β -actin content. The results are representative of four different experiments 
performed in triplicate (n = 4) (***p < 0.001 EC+ IL-3-EVs and 1*6STAT5-EVs vs EVs, EC+ IL-3-Δ N-EVs 
vs IL-3-EVs and 1*6STAT5-EVs for pSTAT5 in a; ***p < 0.001 EC+ IL-3-Δ N-EVs vs all experimental groups 
for STAT5 in a; **p < 0.01 EC+ IL-3-EVs and 1*6STAT5-EVs vs EVs, ***p < 0.001 EC+ IL-3-Δ N-EVs vs IL-
3-EVs and 1*6STAT5-EVs for cyclin D1 in b). (c) Representative ChIP analysis of STAT5 binding to the cyclin 
D1 promoter region using ECs treated for 24 h as indicated; data, normalized to the corresponding input values 
(mean ± SEM), are reported as relative amount of PCR products (n = 4) (**p < 0.01 EC+ IL-3-EVs vs EVs, IL-
3-Δ N-EVs vs EC+ IL-3-EVs and 1*6STAT5-EVs).
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that IL-3-EV cargo might merely reproduce the intracellular pSTAT5 content. Alternatively, IL-3-EV cargo might 
reflect the relevance of pSTAT5 for IL-3-mediated paracrine actions. As a matter of fact, STAT5 has been reported 
to strictly control the proliferation and arterial specification of endothelial progenitor cells, thus resulting in 
neovessel formation5. This effect is mediated by cyclin D1 expression48. Similarly, IL-3-EVs are able to induce the 
expression of cyclin D1 by transferring the activated STAT5 to neighboring ECs. The concept that the transfer 
of activated STAT5 is crucial to cyclin D1 transcription in response to IL-3-EVs is sustained by the following 
observations: i. IL-3-Δ N-EVs, depleted of pSTAT5, failed to induce cyclin D1 transcription; ii. 1*6STAT5-EVs, 
containing high levels of activated STAT5, were able to induce cyclin D1 transcription even in the absence of IL-3. 
Proof of the role of the activated STAT5 transferred by IL-3-EVs in promoting pro-angiogenic signals has also 
been provided by functional studies performed with IL-3-Δ N-EVs and 1*6STAT5-EVs. Tridimentional tube-like 
structure formation, in response to IL-3-EVs, can be recapitulated by 1*6STAT5-EVs even in the absence of IL-3. 
Finally, the failure of both IL-3 and IL-3-EVs to promote pro-angiogenic signals in recipient ECs depleted of 
STAT5 provides the proof of concept that pSTAT5 intracellular content5,34 is crucial for EC functional activities.
EC activation most likely contributes to changing EV levels and contents, ultimately influencing their func-
tions. It has been reported that EV release is enhanced in ECs and leukocytes exposed to inflammatory stim-
uli49,50, however the molecular mechanisms regulating these processes have so far remained elusive. In the present 
study, we demonstrate that STAT5 activation by IL-3 also controls the release and trafficking of EVs from parental 
to recipient cells. More importantly, we demonstrate that STAT5 activation, in an inflammatory microenviron-
ment containing IL-3, provides the machinery for ECs to arrange their EV miR-126-3p cargo without disturbing 
miR-126-3p intracellular content. This implies that IL-3, after binding to its receptor, can both directly influence 
cell behavior as well as driving cell-to-cell signaling through EV secretion and reuptake by neighboring cells. 
Moreover, the failure to obtain further biological effects from using IL-3-EVs together with IL-3 (data not shown) 
sustains the notion that IL-3-EVs can transfer the relevant machinery to boost pro-angiogenic signals in the tissue 
site of inflammation by themselves.
In physiological conditions, quiescent endothelium secretes EVs that inhibit monocyte activation and sup-
press EC activation51. In the present study, we provide evidence to show that EC-EVs, in an inflammatory setting 
containing IL-3, mediate the horizontal transfer of bioactive proteins, miRs and their precursors, such as pSTAT5, 
miR-126-3p and pre-miR-126, which independently, could boost the local adaptation to wound healing (Fig. 8). 
Figure 6. EV pSTAT5 content mediates IL-3-EV biological effects. (a,b) Representative photomicrographs 
of an in vitro angiogenesis assay performed on ECs treated with EC-derived EVs, as indicated, in a or on ECs 
transfected with Δ NSTAT5 (Δ N) and treated as indicated in (b). Quantitative analysis of in vitro formed  
vessel-like structures (number and length of branches, percentage of area) is reported as mean ± SD. The results  
are representative of four different experiments performed in triplicate (n = 4) (for length, ***p < 0.001 EC+  
IL-3-EVs and 1*6STAT5-EVs vs EVs, EC+ IL-3-Δ N-EVs vs IL-3-EVs and 1*6STAT5-EVs; for % area 
**p < 0.01 EC+ IL-3-EVs vs EVs, *p < 0.05 ECs+ 1*6STAT5-EVs vs EVs, EC+ IL-3-Δ N-EVs vs IL-3-EVs and 
1*6STAT5-EVs; for n° of branches, *p < 0.05 ECs+ IL-3-EVs vs EVs). Scale bars indicate 50 μ m. (a,b).
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Moreover, since EVs have gained significant interest as potential biomarkers and pharmacological targets of vas-
cular damage, our data suggest that pSTAT5 may represent a specific IL-3-EV protein signature.
Figure 7. STAT5 dictates the release of EV and miR-126-3p cargo in response to IL-3 stimulation. (a) Number 
of EV particles (mean ± SEM) calculated per cell at isolation. Data refer to EVs recovered from untreated or  
IL-3-treated ECs or from ECs transfected with Δ NSTAT5, in the presence of IL-3, or with 1*6STAT5 constructs for 
48 h. Results are representative of four different experiments performed in triplicate (n = 4) (***p < 0.001, IL-3-EVs 
vs EVs, IL-3-Δ N-EVs vs IL-3-EVs; **p < 0.01 1*6STAT5-EVs vs IL-3-Δ N-EVs). (b) miR‐126-3p, normalized to 
RNU6B, was evaluated on EVs recovered from ECs, treated as above (n = 4) (p = 0.01 IL-3-EVs vs EVs, p = 0.01 
IL-3-Δ N-EVs vs IL-3-EVs, p = 0.04 1*6STAT5-EVs vs IL-3-Δ N-EVs). (c) miR‐126-3p was evaluated by qRT-PCR 
on ECs untreated or treated with IL-3 or transfected with Δ NSTAT5, in the presence of IL-3, or with 1*6STAT5 
constructs. Data normalized to RNU6B are representative of four different experiments performed in triplicate 
(n = 4). (d) miR‐126-3p expression was evaluated by qRT-PCR on ECs untreated or treated with EVs derived 
from ECs as indicated. Data normalized to RNU6B are representative of four different experiments performed 
in triplicate (n = 4) (p = 0.04 EC+ IL-3-EVs vs EC+ EVs, p = 0.01 EC+ IL-3-Δ N-EVs vs IL-3-EVs, p = 0.008 
ECs+ 1*6STAT5-EVs vs IL-3-Δ N-EVs). (e,f) Cell lysates from ECs treated with EC-derived EVs, as indicated, 
were analyzed for Spred-1 (e) or for pErk1/2 (f ) content and normalized to β -actin or Erk1/2 content, respectively 
(n = 4) (***p < 0.001 EC+ IL-3-EVs and 1*6STAT5-EVs vs EVs, EC+ IL-3-Δ N-EVs and anti-miR-126 IL-3-EVs 
vs IL-3-EVs and 1*6STAT5-EVs for Spred-1 in e; **p < 0.01 EC+ IL-3-EVs and 1*6STAT5-EVs vs EVs, EC+ I 
L-3-Δ N-EVs and anti-miR-126 IL-3-EVs vs IL-3-EVs and 1*6STAT5-EVs for pErk1/2 in (f ). (g) Cell extracts from 
ECs untreated or treated with IL-3 for 15 minutes, or from Δ NSTAT5-transfected ECs, in the presence or in the 
absence of IL-3, were analyzed for pErk1/2 content, normalized to Erk1/2 content (n = 4) (***p < 0.001 EC+ IL-3 
vs none, EC+ Δ NSTAT5+ IL-3 vs NSTAT5).
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Methods
Figure 8. Schematic representation of IL-3 paracrine actions via EC-EVs. IL-3 stimulation leads to Erk1/2 
activation. IL-3 stimulation leads to STAT5 activation and cyclin D1 transcription48. On the other hand, IL-3-
mediated STAT5 activation is involved in the control of EV cargo (at least of pSTAT5, miR-126-3p EV content) 
and EV release (left panel). The released vesicles are internalized by neighboring ECs. The transfer of EV-
miR126-3p and pSTAT5 into recipient ECs independently promotes pro-angiogenic signals (right panel).
Description Purchased from
Reagents
Bovine calf serum (BSA) (A8806), FCS (12138C), FBS (F6178), SDS (L3771), PIPES 
(P9291), Triton X-100 (T8787), Nonidet P-40 (74385), NaCl (S3014), NaF (S7920), 
Na3OV4 (S6508), Na4P2O7 (P8010), MgCl2 (M8266), KCl (P9541), HCl (258148), 
Na-azide (S2002), Hepes (H3375), Tris (T1503), EDTA (E6758), EGTA (E4378), 
ethanol (51976), aprotinin (A6279), pepstatin A (P5318), PMSF (P7626), DMSO 
(D8418), PKH26 dye (MINI26-1KT), Medium 199 (M4530), leupeptin (L2884), 
penicillin-streptomycin (P4333), Trypsin (T4799), α -amanitin (A2263)
Sigma-Aldrich (St Louis, MO, USA)
Protein molecular weight markers (161-0374), Acrylammide (161-0156), 
polyvinylidene difluoride (PVDF) membranes (162-0115), Bradford reagent 
(500–0205), ECL (170–5061)
Bio-Rad (Hercules, CA, USA)
Matrigel Basement Membrane Matrix Growth Factor Reduced (356231) BD Bioscience Pharmingen (Franklin Lakes, NJ, USA)
Lipofectin® Reagent (18292-037), TRIZOL (15596018), hsa-miR-126-3p (002228), RNU6B (001093), hsa-miR-221 (000524), hsa-miR-222 (002276), has-miR-126-3p 
Anti-miR™ miRNA Inhibitor (AM12841, MIMAT0000445), RNU48 (001006)
InvitrogenTM (Life Technologies Carlsbad, CA, USA; 
Paisley, UK).
Human recombinant IL-3 (200-03)
PeproTech EC Ltd (London, UK)
Human recombinant IL-1β (200-1B)
Human recombinant TNF-α (300-01A) 
Human recombinant bFGF (100-18B)
Antibodies
anti-CD105-FITC (1F-298-T100) anti-CD81-PE (1P-588-T100) EXBIO Praha AS (Vestec, CR)
anti-CD31-FITC (130-092-654) Miltenyi Biotec GmbH (Bergisch Gladbach, Germany)
anti-CD146-FITC (5050-F100T) BioCytex SARL (Marseille France)
anti-Spred-1 (sc-393198) 
S. Cruz Biotechnology (Heidelberg, Germany)
anti-pErk1/2 MAPK (sc-16982)
anti-Erk1/2 MAPK (sc-93)
anti-β actin (sc-47778)
anti CD63 (sc-15363)
anti cyclin D1 (sc-20044)
anti-goat IgG-FITC (sc-2356)
anti-rabbit IgG-PE( sc-3739)
anti-goat IgG-PE (sc-3743)
anti-KDR (sc-504)
anti-c-Kit/CD117 (sc-13508)
anti-STAT5 (sc-835)
anti-STAT3 (sc-483)
anti-pSTAT3 (9131S)
Cell Signaling Technology (Danvers MA, USA)
anti-pSTAT5 (9314S)
Human IL-3 R alpha Antibody (MAB301) R&D System Inc. (Minneapolis, MN, USA)
Continued
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:25689 | DOI: 10.1038/srep25689
Cell cultures. Endothelial cells (ECs) were isolated from the human umbilical vein by Trypsin treatment 
within 4 hours of delivery (0.1%, w/v), were cultured in M199 with the addition of 20% (v/v) BCS and 5 ng/ml of 
bFGF and used at early passage (II-III)52. To collect EVs, ECs were starved in M199 deprived of BCS for 24 h, treated 
or not with IL-3 (10 ng/ml). Cell viability was evaluated by trypan blue at the end of each experiment (94 ± 5% 
viable cells/experiment). Where indicated, ECs were pre-incubated with the anti-IL-3R antibody (20 μ g/ml) 
30 minutes before IL-3 treatment. In selected experiments, EVs were recovered from oligonucleotide- or 
construct-transfected ECs, as described below, or from IL-1β (10 ng/ml) or TNF-α (10 ng/ml) treated ECs. 
In addition, EVs were recovered from IL-3-stimulated ECs pretreated with JAK2 inhibitor (20μ M). ECs were 
also cultured in M199 without BCS for 24 h in the presence of EC-derived EVs, as indicated. In preliminary 
studies a dose response curve was performed to evaluate the number of EVs needed to obtain the best bio-
logical response. We tested different EV numbers (from 1 to 8 × 103) per target cell (10 × 104 cells/well/2 ml). 
We found that 5 × 103 EVs/target cell was the most effective EV dose. Thus, 5 × 103 EVs/target cell were used 
throughout the study. All experiments were performed in accordance with the European Guidelines and poli-
cies and approved by the Ethical Committee of the University of Turin. Ethical approval was also obtained from 
Azienda Ospedaliero-Universitaria (AOU), Città della Salute e della Scienza di Torino, Italy. Informed consent 
was obtained from all subjects in accordance with the Declaration of Helsinki.
Isolation of EC-derived EVs. ECs were cultured in M199, without BCS, for 24 h in order to collect EVs 
from supernatants. After being centrifuged at 3 k g for 30 minutes to remove debris, cell-free supernatants were 
submitted to differential ultracentrifugation at 10 k and 100 k g (Beckman Coulter Optima L-90K ultracentri-
fuge; Beckman Coulter, Fullerton, CA) for 3 h at 4 °C. EVs were either used fresh or were stored at − 80 °C after 
re-suspension in M199 which was supplied with 1% DMSO53. Frozen EVs were washed and pelleted by 100 kg 
ultracentrifugation to remove DMSO before cellular experiments. No difference in biological activity was 
observed between fresh and stored EVs. The protein content of EVs was quantified using the Bradford method 
(Bio-Rad, Hercules, CA, USA). Any possible contamination was tested using a Limulus amebocyte assay (concen-
tration < 0.1 ng/ml) (Charles River Laboratories, Inc., Wilmington, MA, USA). EV size distribution analysis was 
performed using a NanoSight LM10 (NanoSight Ltd, Minton Park UK). The particles in the samples were illumi-
nated using a laser light source and the scattered light was captured by camera and analyzed using Nanoparticle 
Tracking Analysis (NTA). NTA automatically tracked and sized particles according to Brownian motion and 
the diffusion coefficient (Dt). Results were displayed as a frequency size distribution graph and outputted to a 
spreadsheet.
Characterization of EC-derived EVs. Fluorescence-activated cell sorting (FACS) analysis of EC-derived 
EVs was performed as indicated54 using antibodies direct to CD81, CD31, CD105, CD146, KDR and c-Kit 
(also known as CD117), directly or indirectly conjugated with FITC or-PE fluorocrome. FITC or PE mouse 
non-immune isotypic IgG (Dako Cytomation) was used as a control. Briefly, the FACS analysis of EC-derived EVs 
was performed using a Guava easyCyteTM Flow Cytometer (Millipore, Germany). FITC-or PE-conjugated anti-
bodies were added to a suspension of EVs (250 particles/ml in 100μ l) for 15 min at 4 °C in order to perform flow 
cytometric analysis by FACS of EVs. The volume was increased up to 500μ l with a FACS flow and the expression 
of surface markers was evaluated. Surface marker expression is reported as percentage of expression ± SD and 
representative histogram and dot plot analysis are reported in the Supplementary Figures. CD63 content in EVs 
was analyzed by western blot.
EV internalization by ECs. The internalization of EVs into ECs was evaluated using confocal microscopy 
(LSM5-PASCAL; Zeiss, Oberkochen, Germany). A pool of approximately 2.5 × 108 EV particles was labeled with 
red fluorescent PKH26 dye (2 μ l/ml) for 30 min at 37 °C and then EVs were washed and ultracentrifuged at 100 k g 
for 1 h at 4 °C. EV pellets were suspended in M199 and added to ECs (1 × 106) for several hours in order to detect 
their internalization (photomicrographs reported in the results show EV internalization after 1 h)55. Z-stack con-
focal microscopy EC images were also obtained.
Transmission electron microscopy. Transmission electron microscopy (TEM) was performed on EVs 
isolated by ultracentrifugation resuspended in PBS, placed on 200 mesh nickel formvar carbon coated grids 
(Electron Microscopy Science, Hatfield, PA) and left to adhere for 20 min. Grids were then incubated with 2.5% 
glutaraldehyde containing 2% sucrose and after washings in distilled water the EVs were negatively stained with 
NanoVan (Nanoprobes, Yaphank, NK, USA) and observed by Jeol JEM 1010 electron microscope (Jeol, Tokyo, 
Japan).
Description Purchased from
anti-rabbit IgG, HRP linked (4050-05)
Southern Biotech (Birmingham, Alabama USA)
anti-mouse IgG, HRP linked (1031-05)
Tyrphostin AG-490 (19-146) Merck S.p.a.(Vimodrone, MI, Italy)
anti-mouse IgG-PE (550589)
BD Bioscience Pharmingen (Franklin Lakes, NJ, USA)
anti-mouse and rabbit IgG-FITC (555988 and 554020)
Table 1. Reagents and Antibodies.
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Western blot analysis. ECs and EVs were lysed and protein concentrations obtained as previously 
described56. 50 μ g protein for cells and 10 μ g for EVs were subjected to SDS-PAGE, transferred into nitrocellulose 
membranes and processed as previously described56. Densitometric analysis was used to calculate the differences 
in the fold induction of protein levels which were normalized to STAT5, STAT3, β -actin, CD63 or Erk1/2 content. 
Values are reported as relative amounts.
RNA isolation and quantitative real-time PCR (qRT-PCR). Total RNA was isolated from ECs using 
the TRIzol reagent (Invitrogen) and from different EVs using the mirVana RNA isolation kit (Ambion), according 
to manufacturer’s instructions. RNA was quantified spectrophotometrically (Nanodrop ND-1000, Wilmington, 
DE, USA) because intact 18S and 28S rRNAs were difficult to detect in the EVs. RNA quality was assessed on an 
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Cruz, CA) using tan Agilent small RNA kit (Agilent 
Technologies). RNA from cells and EVs was then reverse-transcribed using a TaqMan microRNA RT kit, specific 
for miR-126-3p, miR-221 and miR-222, and subjected to quantitative real-time-PCR (qRT-PCR) using a TaqMan 
microRNA assay kit and the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, 
USA). miR expression was normalized to the small nuclear RNA, RNU6B or RNU48. In selected experiments, 
loss-of-function approaches were performed in ECs that had been transfected for 48 h with the anti-miR negative 
control or the anti-miR-126-3p antagomir (Applied Biosystems). EV isolation was then obtained from ECs that 
had been depleted of miR-126-3p. In selected experiments, total RNA, isolated from ECs by TRIzol or from EVs 
by mirVana RNA extraction kit after DNAse digestion, was subjected to reverse RT-PCR with specific prim-
ers: IL-3 (sense, 5′ -GCCCGTCCTGCTCCTGCTCCA-3′ ; antisense, 5′ -CCGGAATTCA-TTC-CAGTCAC-3′ ) 
a n d  β  - a c t i n  ( s e n s e ,  5 ′  - G G T C A T C T T C T C G C G G T T G G C C T T G G G G T - 3 ′  ; 
antisense, 5′ -CCCCAGGCACCAGGGCGTGAT-3′ ). Total RNA from IL-3 producing gibbon MLA cell line was 
used as a control (+ ). In selected experiments, total RNA, isolated from ECs by TRIzol or from EVs by mirVana 
RNA extraction kit after DNAse digestion, was assessed by qRT-PCR using miScript Reverse Transcription Kit and 
miScript SYBR Green PCR Kit (both from Qiagen). qRT-PCR was performed using a 96-well StepOne™ Real-Time 
System (Applied Biosystems). The following specific hsa-miR-126-5p (5′ CATTATTACTTTTGGTAC 3′ ) 
and hsa-pre-miR-126 (5′ TGGCGACGGGACATTATT 3′ ) primers were used. miR expression was normalized to 
snoRNA RNU48 (5′ AACTCTGAGTGTGTCGCTGATG 3′ ) and RNU6B (5′ CGCAAGGATGACACGCAA 3′ ).
Transfer of miR-126-3p and pre-miR-126 from EVs to ECs. In order to analyze miR-126-3p and 
pre-miR-126 transfer from IL-3-EVs to ECs, miR transfer experiments were conducted as previously described 
by Yuan57. Approximately 5 × 105 cells/well of ECs were incubated for 24 h with EVs or IL-3-EVs and a transcrip-
tion inhibitor, α -amanitin (Sigma, 50 μ g/ml) or with α -amanitin alone58 to inhibit transcriptional activation 
induced by EVs. Total RNA from ECs, treated as above, was isolated and subjected to qRT-PCR for miR-126-3p 
and pre-miR-126 expression. As an indirect measure of miR transfer, we determined the difference in Ct values 
(Δ Ct) between α -amanitin treated cells in the absence or in the presence of EVs or IL-3-EVs; a positive value 
indicated transfer of miR into target cells (mean ± SD). If no signal was detected, a Ct value of 40 was assigned 
to the sample.
Transfection of dominant negative (ΔN) STAT5 construct and activated form of STAT5. In 
selected experiments, EC cells were transiently transfected with the Δ NSTAT5 construct5 or with the activated 
form of STAT5 (1*6 STAT5A)59 and either cultured in the presence or absence of IL-3 (10 ng/ml). The supernatant 
was collected 48 hours later to isolate EVs and then cells were processed to obtain cell extracts for Western blot 
analysis or total RNA isolation to evaluate miR-126-3p expression.
Tube-like structure formation (in vitro angiogenesis assay). 24-well-plates were coated with growth 
factor-reduced Matrigel matrix to analyze tube-like structure formation by ECs, as previously described35. 
Briefly, ECs were seeded on a Matrigel matrix with or without: IL-3 (10 ng/ml), EVs isolated from unstimu-
lated ECs (EVs), IL-3-treated ECs (IL-3-EVs), IL-3+ anti-IL-3R antibody-treated ECs (anti-IL-3R-EVs), 
IL-3+ Δ NSTAT5-treated ECs (IL-3-Δ N-EVs) and 1*6STAT5-treated ECs (1*6STAT5-EVs). In selected exper-
iments the angiogenesis assay was performed in ECs transfected with the Δ NSTAT5 construct and stimulated 
with IL-3, EVs, or IL-3-EVs. After 6 h, the formation of tube-like structures was evaluated. Phase-contrast images 
(20X magnification) were recorded and the total length of network structures, the number of branches and the 
percentage of vessel area over total area per field were measured using a MicroImage analysis system (Casti 
Imaging, Italy) in five random fields and expressed as a ratio to the respective control (mean ± SD).
Chromatin Immunoprecipitation Assay. The chromatin Immunoprecipitation (ChIP) assay was per-
formed on ECs treated with various EVs as indicated in the Results section, using Magna ChIP A kit (Millipore)34, 
according to the vendor’s instructions. Briefly, ECs, treated as indicated, were cross-linked with 1% formalde-
hyde and quenched before harvest and sonication. The sheared chromatin was immunoprecipitated with the 
anti-STAT5 antibody or control IgG on protein G Sepharose magnetic beads. The eluted IP were digested with 
proteinase K, and DNA was extracted which underwent PCR with primers specific for cyclin D1 promoter 
region: sense, 5′ - GATGCAGTCGCTGAGATTCTT-3′ ; antisense, 5′ -TTGCCCCTGTAGTCCGGTTTT-3′ . The 
non-immunoprecipitated genomic DNA was also analyzed using semi-quantitative real-time PCR and expressed 
as % of the input.
Elisa Assay. To evaluate the levels of bound IL-3 on EVs, IL-3-EVs and anti-IL-3R EVs were measured using 
a colorimetric sandwich enzyme immunoassay (ELISA kit, R&D Systems) as described by the manufacturer’s 
instructions.
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Statistical analysis. All data are presented as mean ± SEM, unless otherwise reported. The D’Agostino–
Pearson test was used to test normality. Data on the in vitro angiogenesis, ELISA and ChIP assays, on RT-PCR, 
miR expression, loss-of-function experiments, α -amanitin experiments, number of recovered EVs per cell and 
lastly on the densitometric analysis for Western blots were analyzed using the Student t tests for 2-group com-
parison and using 1-way ANOVA, followed by Tukey’s multiple comparison test, for ≥ 3 groups. The minimum 
sample size was four experiments performed in triplicate, thus ensuring 90% statistical power between experi-
mental groups, with a probability level of 0.05, two-tailed hypothesis. The cut-off for statistical significance was 
set at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001). All statistical analyses were carried out using GraphPad Prism 
version 5.04 (Graph Pad Software, Inc).
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